Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Successful trade fair appearance at the DGK in Mannheim

The 88th Annual Meeting of the German Society for Cardiology – Cardiovascular Research at the Congress Center Rosengarten in Mannheim was a complete success for Resuscitec GmbH. The CARL Support and the Sales Team introduced the CARL System and CARL Therapy to a professional audience on site from April 20 to 23.

“We experienced great interest in our CARL Therapy and in our CARL System. Many of our conversation partners evaluated the CARL Therapy and the CARL System as a significant milestone in the further development of in-hospital and out-of-hospital resuscitation. Directly at the trade fair, we were able to arrange numerous appointments for product presentations in renowned hospitals throughout Germany”, says Dr. Patrick Rauh, Head of Sales of Resuscitec GmbH.

Over a four-day period, visitors to the trade fair in Mannheim could learn about technical innovations of various medical technology companies. In addition, there were many expert presentations on the topics of cardiology and cardiovascular research.

In his lecture ‘ECMO, Impella, … – When which device?’, Professor Dr. Marcus Hennersdorf gave an outlook on how extracorporeal circulation/ECMO procedures may develop further. He particularly emphasized the technical performance of the CARL System and its innovative, mobile perfusion system and he stressed that using the CARL System enables physicians to resuscitate a person even after a prolonged cardiac arrest without significant sequelae.

< Back